Knowledge Center

Cardiovascular adverse events in cancer patients receiving immune checkpoint inhibitors are often under-detected in clinical trials, partly due to the strict inclusion criteria and limited follow-up typical of such studies. This underscores the need for real-world data analysis to gain a more comprehensive understanding of these events.

Enhancing Hematologic Oncology Data Capture in the OMOP CDM: Methodological Advances and Challenges

Learn more on the results of a multi-center study on cardiovascular toxicities in 1500+ real-world cancer patients treated with immune checkpoint inhibitors

Discover the initial findings of a multi-center study into the real-world usage and adverse events of immune checkpoint inhibitors.

Analysis of Lung Cancer Patient Treatment with Immune Checkpoint Inhibitors Using Natural Language Processing for Data Extraction from Electronic Health Records

Discover the initial findings of the ICI-treated lung cancer patient cohort of 730+ patients regarding demographic and clinical characteristics, ICI treatments, and overall survival (OS).

In collaboration with Heart Center Aalst, we conducted a study in which complete Electronic Health Records of patients were processed and analyzed using LynxCare’s cutting-edge clinical NLP-AI technology in search of phenotypes compatible with aTTR-CM, a rare cardiac disease.

Discover the capabilities of LynxCare’s NLP pipeline through a demo, showcasing how our system performs across multiple languages in diverse healthcare contexts.

To bridge the gap between clinical trial patients and real-world populations, we conducted a comprehensive study in Belgium to characterize cancer patients treated with immune checkpoint inhibitors (ICIs), which have demonstrated survival advantages in various cancer types.